Avise Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Avise provides specialized diagnostic tests for autoimmune diseases including lupus and rheumatoid arthritis that help rheumatologists make faster and more accurate diagnoses.
About
Avise Medical is a specialty diagnostics company founded in 2012 that develops laboratory tests specifically designed to help rheumatologists diagnose and monitor autoimmune diseases including lupus, rheumatoid arthritis, and related conditions. The company's flagship products include AVISE Lupus, a panel of blood biomarkers that increases diagnostic accuracy for systemic lupus erythematosus compared to traditional single-marker tests, and AVISE CTD for connective tissue disease diagnosis. Autoimmune diseases are notoriously difficult to diagnose because symptoms overlap with many other conditions and individual biomarkers have limited sensitivity and specificity. Avise addresses this through multi-biomarker panels that use machine learning to combine signals into diagnostic scores with better performance characteristics. The company works directly with rheumatology practices and provides specialized clinical interpretation support for complex cases. Avise raised over $100M and expanded its diagnostic portfolio to cover monitoring of disease activity and treatment response in addition to initial diagnosis. The company represents the application of advanced biomarker discovery and machine learning to specialty diagnostics in rheumatology.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.